9/15/2009

Elan agreed to sell 18.4% of its equity to Johnson & Johnson for $885 million instead of $1 billion. The move is intended to resolve claims that part of the deal violates Elan's partnership with Biogen Idec for multiple sclerosis drug Tysabri.

Related Summaries